
Posterdiskussion: CLL II

P716 - Significance of Bendamustine (Ribomustin®) in the basic treatment of CLL patients

Günther, G.¹, Bartels, S.²

¹MVZ für Blut- und Krebserkrankungen, PIO (Projektgruppe internistische Onkologie), Potsdam, Deutschland; ²rgb GmbH, Sarstedt, Deutschland

Introduction: Bendamustine has been applied in the therapy of CLL for more than 30 years now. It is highly effective and well compatible^{1,2,3}. Nevertheless, there are just a few publications documenting individually adapted applications of Bendamustine which are characterised by a large therapeutic window. The aim of this project within the framework of analysing the patients' treatment in ambulant practices specialising in oncological treatment is to demonstrate these alternatives taking into consideration the quality of the therapy.

Methods: Since May 2008, 198 patients were reported and 58 were documented. 48 patients have been analysable so far. 44 medical practices specialising in oncological treatment are involved in the survey. 1 (2%) patient had a BINET stage A, 25 (52%) stage B and 22 (46%) stage C before the start of the therapy. The median age was 73 years (45-91 years). 32 (67%) were male, 16 (33%) female. 36 (75%) patients received a monotherapy, 9 (19%) a combination with prednisone, resp. dexamethasone and 3 (6%) of rituximab.

Results: 22 (46%) patients received a 1st-line therapy, 11 (23%) a 2nd-line and 15 (31%) a 3rd-line therapy. The median of 3 cycles was administered (1-8). The monthly application rate of bendamustine amounts to 170 mg/m² (38-365 mg/m²). The objective response rate (CR/PR) is 77 %. It was 86% when administered as primary therapy.

Conclusions: Bendamustine induces high response rates and is already applied as 1st-line therapy with half of the patients also in clinical practice. The data acquisition is being continued, the analysis shall be presented in a timely manner.

¹Anger 1975, ²Kath 2001, ³Knauf 2007

Disclosure:

No conflicts of interest